SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Cannabis >

InMed Pharmaceuticals Inc (CNSX:IN)

CNSX:IN RSS Feed
Add CNSX:IN Price Alert      Hide Sticky   Hide Intro
Moderator: whatarush12
Search This Board: 
Last Post: 6/15/2017 3:11:52 AM - Followers: 0 - Board type: Free - Posts Today: 0

OVERVIEW

InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.

InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.


BOARD OF DIRECTORS

Eric A. Adams

President & CEO

Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada’s Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Adam Cutler, B.A.

Director

Mr. Cutler has over 19 years of experience in the global healthcare industry where he successfully held senior leadership positions in various roles from Equity Research, Corporate Affairs and Strategy, Investor Relations and Consulting. Mr. Cutler earned a reputation as a top-ranked biotechnology sell-side analyst and advisor, with extensive knowledge of biotech product development, the global healthcare environment, and the US financial community

Mr. Cutler is currently Senior Vice President of Corporate Affairs at Arbutus Biopharma and previously was Managing Director at The Trout Group LLC and Trout Capital LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. Mr. Cutler spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities, with prior analytical and consulting experience at The Frankel Group and Ernst & Young, Healthcare Consulting.

Mr. Cutler holds a BA in Economics from Brandeis University.

Bill Garner, M.D.

Director

Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, M&A or IPO transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as Chairman & Founder of Update Pharma and as a Director at IGXBio; previously serving as CEO of Invion Limited (ASX:IVX), a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded; and as a co-founder and Director of Del Mar Pharmaceuticals (OCTQX:DMPID). Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche’s oncology division. Prior to Roche, Dr. Garner was a healthcare merchant banker in New York City.

He has a Master of Public Health from Harvard and earned his M.D. at New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York.

Andrew Hull, B.A.

Director

Mr. Hull has over 30 years’ experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He currently serves as Vice President of Global Alliances for Takeda Pharmaceuticals where he is responsible for maximizing the success of Takeda’s growing number (40+) of commercial and R&D partnerships with many of the industry’s leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda’s US portfolio of over $3B including diabetes, neuroscience, GI and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Labs.

Mr. Hull received a bachelor’s degree in biology from Kenyon College in 1985. He serves as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and is a member of the Kenyon College Board of Trustees.

Martin Bott, MIBS

Director

Mr. Bott brings over 28 years’ experience in senior financial and executive leadership to InMed’s Board of Directors. He currently serves as VP of Corporate Finance and Investment Banking at Eli Lilly & Company. He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.

Mr. Bott has a Bachelor’s of Business / Marketing (Cologne, Germany, 1985) and a Master’s in International Business Studies (University of South Carolina, 1988).


MANAGEMENT

Eric A. Adams

President & CEO

Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada’s Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Dr. Sazzad Hossain, Ph.D., M.Sc.

Chief Scientific Officer

Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

Dr. Ado Muhammed, MD, DPM, MFPM

Chief Medical Officer

Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed’s received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

Alexandra D.J. Mancini, M.Sc.

Senior Vice President, Clinical and Regulatory Affairs.

Ms. Mancini has over 30 years’ of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, verseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; linical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions.

Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.

Chris Bogart

SVP, Corporate Strategy & Investor Relations

Mr. Bogart is a co-founder of InMed Pharmaceuticals and currently serves as the SVP of Corporate Strategy and Investor Relations. Mr. Bogart has over 18 years in international business development, strategic decision-making and planning. Mr. Bogart is a seasoned capital markets professional with an extensive background in equity financings and strategic communications for publicly traded companies in a senior management role. He has planned, executed and maintained Investor Relations & Communication initiatives in Canada, United States and Europe.

Jeff Charpentier

CFO, Chief Financial Officer

Chief Financial Officer

Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.


PIPELINE

InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.


Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.

INM-750 includes multiple cannabinoids as the active ingredients:

  • The cannabinoids included in INM-750 were selected to modulate keratin levels in patients with EB with the expectation of having a disease modulating effect
    A secondary consideration in selection of the cannabinoids was addressing symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain
    INM-750 is being developed for topical application, designed to maximize penetration of the cannabinoids to the epidermal / dermal junction in the skin.

 

INM-085

Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.

INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.

INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.

CNSX:IN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CNSX:IN News: Honeywell Completes Acquisition Of Intermec 09/17/2013 08:34:00 AM
CNSX:IN News: BofI Set to Join the S&P SmallCap 600 09/16/2013 05:43:00 PM
CNSX:IN News: Federal Trade Commission Grants Early Termination of Waiting Period for Acquisition of Intermec by Honeywell International Inc. 09/13/2013 03:25:00 PM
CNSX:IN News: Intermec Strengthens Industrial Printer Portfolio with New Mid-Range Label Printer 09/05/2013 09:00:00 AM
CNSX:IN News: Intermec Strengthens Industrial Printer Portfolio with New Mid-Range Label Printer 09/05/2013 09:00:00 AM